Filing Details

Accession Number:
0001209191-22-001700
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-05 16:30:21
Reporting Period:
2022-01-04
Accepted Time:
2022-01-05 16:30:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1662579 C4 Therapeutics Inc. CCCC Biological Products, (No Disgnostic Substances) (2836) 475617627
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1825445 Adam Crystal C/O C4 Therapeutics, Inc.
490 Arsenal Way #200
Watertown MA 02472
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-04 15,000 $6.49 30,000 No 4 M Direct
Common Stock Disposition 2022-01-04 13,946 $31.59 16,054 No 4 S Direct
Common Stock Disposition 2022-01-04 1,054 $32.66 15,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-01-04 15,000 $0.00 15,000 $6.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
112,292 2029-04-08 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.32 to $33.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  4. 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter.